Immune cells as anti-cancer therapeutic targets and tools

Journal of Cellular Biochemistry

Volumn 101, Issue 4, 2007, Pages 918-926

  Johansson, Magnus ^a   Tan, Tingting ^a   De Visser, Karin E ^a,c   Coussens, Lisa M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Adative; Cancer; Immune cells; Inflammation; Innate

Indexed keywords

CANCER GROWTH; CANCER IMMUNOLOGY; CANCER RISK; CELL INTERACTION; CELLULAR IMMUNITY; CHRONIC INFLAMMATION; HUMAN; HUMORAL IMMUNITY; IMMUNOBIOLOGY; IMMUNOCOMPETENCE; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR IMMUNITY; TUMOR IMMUNOLOGY;

ANIMALS; ANTIBODY FORMATION; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, NATURAL; MODELS, IMMUNOLOGICAL; NEOPLASMS;

EID: 34447291142     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21230     Document Type: Review

References (57)

1. Agarwal A, Verma S, Burra U, Murthy NS, Mohanty NK, Saxena S. 2006. Flow cytometric analysis of Th1 and Th2 cytokines in PBMCs as a parameter of immunological dysfunction in patients of superficial transitional cell carcinoma of bladder. Cancer Immunol Immunother 55:734-743.
2. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP, Gabrilovich DI. 2001. Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer. J Immunol 166:678-689.
3. Balkwill F, Mantovani A. 2001. Inflammation and cancer: Back to Virchow? Lancet 357:539-545.
4. Balkwill F, Charles KA, Mantovani A. 2005. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7:211-217.
5. Bansal SC, Bansal BR, Thomas HL, Siegel PD, Rhoads JE Jr, Cooper DR, Terman DS, Mark R. 1978. Ex vivo removal of serum IgG in a patient with colon carcinoma: Some biochemical, immunological and histological observations. Cancer 42:1-18.
6. Barbera-Guillem E, May KF Jr, Nyhus JK, Nelson MB. 1999. Promotion of tumor invasion by cooperation of granulocytes and macrophages activated by anti-tumor antibodies. Neoplasia 1:453-460.
7. Benoist C, Mathis D. 2002. Mast cells in autoimmune disease. Nature 420:875-878.
8. Cerhan JR, Anderson KE, Janney CA, Vachon CM, Witzig TE, Habermann TM. 2003. Association of aspirin and other non-steroidal anti-inflammatory drug use with incidence of non-Hodgkin lymphoma. Int J Cancer 106:784-788.
9. Coca S, Perez-Piqueras J, Martinez D, Colmenarejo A, Saez MA, Vallejo C, Martos JA, Moreno M. 1997. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 79:2320-2328.
10. Coussens LM, Werb Z. 2002. Inflammation and cancer. Nature 420:860-867.
11. Coussens LM, Hanahan D, Arbeit JM. 1996. Genetic predisposition and parameters of malignant progression in K14- HPV16 transgenic mice. Am J Path 149:1899-1917.
12. Coussens LM, Shapiro SD, Soloway PD, Werb Z. 2001. Models for gain-of-function and loss-of-function of MMPs. Transgenic and gene targeted mice. Methods Mol Biol 151:149-179.
13. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942-949.
14. de Visser KE, Korets LV, Coussens LM. 2005. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7:411-423.
15. de Visser KE, Eichten A, Coussens LM. 2006. Paradoxical roles of the immune system during cancer development. Nature Reviews Cancer 6:24-37.
16. Degli-Esposti MA, Smyth MJ. 2005. Close encounters of different kinds: Dendritic cells and NK cells take centre stage. Nat Rev Immunol 5:112-124.
17. Dudley ME, Rosenberg SA. 2003. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 3:666-675.
18. Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. 2003. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 26:332-342.
19. Engle SJ, Ormsby I, Pawlowski S, Boivin GP, Croft J, Balish E, Doetschman T. 2002. Elimination of colon cancer in germ-free transforming growth factor beta 1-deficient mice. Cancer Res 62:6362-6366.
20. Ernst PB, Gold BD. 2000. The disease spectrum of Helicobacter pylori: The immunopathogenesis of gastroduodenal ulcer and gastric cancer. Annu Rev Microbiol 54:615-640.
21. Farrow B, Evers BM. 2002. Inflammation and the development of pancreatic cancer. Surg Oncol 10:153-169.
22. Finke J, Ferrone S, Frey A, Mufson A, Ochoa A. 1999. Where have all the T cells gone? Mechanisms of immune evasion by tumors. Immunol Today 20:158-160.
23. Gabrilovich DI, Velders MP, Sotomayor EM, Kast WM. 2001. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol 166:5398-5406.
24. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F. 2006. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960-1964.
25. Giraudo E, Inoue M, Hanahan D. 2004. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 114:623-633.
26. Hainsworth JD, Litchy S, Barton JH, Houston GA, Hermann RC, Bradof JE, Greco FA. 2003. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 21:1746-1751.
27. Hamerman JA, Ogasawara K, Lanier LL. 2005. NK cells in innate immunity. Curr Opin Immunol 17:29-35.
28. Hayakawa Y, Takeda K, Yagita H, Smyth MJ, Van Kaer L, Okumura K, Saiki I. 2002. IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide. Blood 100:1728-1733.
29. Hoebe K, Janssen E, Beutler B. 2004. The interface between innate and adaptive immunity. Nat Immunol 5:971-974.
30. Hogarth PM. 2002. Fc receptors are major mediators of antibody based inflammation in autoimmunity. Curr Opin Immunol 14:798-802.
31. Imada A, Shijubo N, Kojima H, Abe S. 2000. Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma. Eur Respir J 15:1087-1093.
32. Kanazawa M, Yoshihara K, Abe H, Iwadate M, Watanabe K, Suzuki S, Endoh Y, Takita K, Sekikawa K, Takenoshita S, Ogata T, Ohto H. 2005. Effects of PSK on T and dendritic cells differentiation in gastric or colorectal cancer patients. Anticancer Res 25:443-449.
33. Kazkaz H, Isenberg D. 2004. Anti B cell therapy (rituximab) in the treatment of autoimmune diseases. Curr Opin Pharmacol 4:398-402.
34. Kuper H, Adami HO, Trichopoulos D. 2000. Infections as a major preventable cause of human cancer. J Intern Med 248:171-183.
35. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL. 1996. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 56:4625-4629.
36. Leek RD, Landers RJ, Harris AL, Lewis CE. 1999. Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer 79:991-995.
37. Lin EY, Nguyen AV, Russell RG, Pollard JW. 2001. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 193:727-740.
38. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA. 2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314:126-129.
39. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. 1999. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 59:3128-3133.
40. Orange JS, Ballas ZK. 2006. Natural killer cells in human health and disease. Clin Immunol 118:1-10.
41. Peek RM Jr, Mohla S, DuBois RN. 2005. Inflammation in the genesis and perpetuation of cancer: Summary and recommendations from a national cancer institute-sponsored meeting. Cancer Res 65:8583-8586.
42. Raulet DH. 2004. Interplay of natural killer cells and their receptors with the adaptive immune response. Nature immunology 5:1038-1114.
43. Ribatti D, Ennas MG, Vacca A, Ferreli F, Nico B, Orru S, Sirigu P. 2003. Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma. Eur J Clin Invest 33:420-425.
44. Schernhammer ES, Kang JH, Chan AT, Michaud DS, Skinner HG, Giovannucci E, Colditz GA, Fuchs CS. 2004. A prospective study of aspirin use and the risk of pancreatic cancer in women. J Natl Cancer Inst 96:22-28.
45. Serafini P, De Santo C, Marigo I, Cingarlini S, Dolcetti L, Gallina G, Zanovello P, Bronte V. 2004. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother 53:64-72.
46. Shacter E, Weitzman SA. 2002. Chronic inflammation and cancer. Oncology 16:217-226.
47. + T cells: A common basis between tumor immunity and autoimmunity. J Immunol 163:5211-5218.
48. Smyth MJ, Crowe NY, Godfrey DI. 2001. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol 13:459-463.
49. Sparmann A, Bar-Sagi D. 2004. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 6:447-458.
50. Tlsty TD, Coussens LM. 2006. Tumor stroma and regulation of cancer developemnt. Annual Rev Pathol: Mechan of Disease 1:119-150.
51. Ulrich CM, Bigler J, Potter JD. 2006. Non-steroidal antiinflammatory drugs for cancer prevention: Promise, perils and pharmacogenetics. Nat Rev Cancer 6:130-140.
52. Vlock DR, Arnold B, Humpierres J, Schwartz DR, Baker SR, Krause CJ, Swanson N, Carey TE. 1992. Serial studies of autologous antibody reactivity to squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 34:329-336.
53. Wasserman J, Glas U, Blomgren H. 1975. Autoantibodies in patients with carcinoma of the breast. Correlation with prognosis. Clin Exp Immunol 19:417-422.
54. Williams RR. 1992. Recognition: Fichte and Hegel on the Other. New York: SUNY Press.
55. + cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6:409-421.
56. Zitvogel L, Tesniere A, Kroemer G. 2006. Cancer despite immunosurveillance: Immunoselection and immunosubversion. Nat Rev Immunol 6:715-727.
57. Zou W. 2005. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5:263-274.